With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...
The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Eli Lilly is just weeks away from launching Mounjaro ... In the US, tirzepatide is sold as Mounjaro for diabetes and under the Zepbound brand for overweight and obesity and is currently available ...
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive ...
Nvidia was falling early on Tuesday as it faces an antitrust investigation in China, despite a sales boost from key supplier ...
The Virco Mfg. Corporation ( NASDAQ:VIRC ) share price has had a bad week, falling 19%. But that doesn't change ...